Ken Griffin Seres Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 248,600 shares of MCRB stock, worth $198,880. This represents 0.0% of its overall portfolio holdings.
Number of Shares
248,600
Previous 190,300
30.64%
Holding current value
$198,880
Previous $180,000
14.44%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding MCRB
# of Institutions
75Shares Held
41.3MCall Options Held
2.96MPut Options Held
228K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$18.5 Million5.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.87MShares$4.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.01MShares$1.61 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.81MShares$1.45 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.76MShares$1.41 Million0.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $99.3M
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...